Name: Tauroursodeoxycholic Acid (TUDCA)
Brand: Selleck Chemicals
SKU: S3654
Availability: InStock
Rating: 5 (36 reviews)

Jump to

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	HSP JNK Antioxidant ROS eIF IRE1 PERK PDI PKR ASK
Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CHO cells	Function assay			Agonist activity at human TGR5 expressed in CHO cells by luciferase assay, EC50=30 μM	18307294
Sf9	Function assay			TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells, Km=4.1μM	10648470
MDCK	Function assay			TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells, Km=6.6μM	11093941
HEK293	Function assay		90 mins	Inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in choline release from LPC measured every 30 secs for 90 mins by HVA based fluorescence assay, IC50=10.3μM	28165241
Sf9	Function assay			TP_TRANSPORTER: uptake in membrane vesicles isolated from Bsep-expressing Sf9 cells, Km=11.9μM	12404240
CHO	Function assay			TP_TRANSPORTER: uptake in Ntcp-expressing CHO cells, Km=14μM	9486191
COS	Function assay			TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells, Ki=28μM	9458785
HuH7	Cytoprotective assay		6 hrs	Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of CHOP mRNA levels after 6 hrs	27729186
HuH7	Cytoprotective assay		6 hrs	Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs	27729186
HuH7	Cytoprotective assay		6 hrs	Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs	27729186
HuH7	Cytoprotective assay		6 hrs	Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs	27729186
HuH7	Cytoprotective assay		6 hrs	Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs	27729186
HuH7	Cytoprotective assay		6 hrs	Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as reduction in XBPs/XBPu ratio after 6 hrs	27729186
HuH7	Cytoprotective assay	1 mM	24 hrs	Cytoprotective activity against DCA-induced cell death in human HuH7 cells assessed as increase in cell viability at 1 mM preincubated with cells followed by DCA addition measured after 24 hrs by MTT/INCELL assay	27729186
HuH7	Cytoprotective assay		6 hrs	Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of BIP/GRP78 mRNA levels after 6 hrs	27729186
HEK293	Function assay			Non-competitive inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in LPC hydrolysis by Lineweaver-Burk plot analysis	28165241
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (200.12 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : 50 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	499.70	Formula	C₂₆H₄₅NO₆S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	14605-22-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

In vitro	Tauroursodeoxycholic acid (TUDCA) is an endogenous hydrophilic tertiary bile acid produced in humans at a low level. In ER stress conditions, treatment with this compound reduces the activation of ER stress-associated proteins, including GRP78, PERK, eIF2α, ATF4, IRE1α, JNK, p38, and CHOP, and inhibits the dissociation between GRP78 and PERK, resulting in reduced ER stress-mediated cell death. It also increases PrP^C (Cellular prion protein) expression. TUDCA regulates stem cell differentiation into various lineages such as adipogenic and osteogenic lineages. It attenuates ER stress, prevents unfolded protein response dysfunction, and stabilizes mitochondria. Under ER stress, treatment with this compound significantly increases the expression of BCL-2 and significantly decreases the expression of Bax, cleaved caspase-3, and cleaved PARP-1, compared with that of untreated cells.
In vivo	Tauroursodeoxycholic Acid (TUDCA) is effective for treating cholestatic liver diseases and also has an ameliorating effect on several diseases, including neurodegenerative diseases, osteoarthritis, vascular diseases, and diabetes. In a murine hindlimb ischemia model, TUDCA-treated mesenchymal stem cells (MSCs) transplantation augments the blood perfusion ratio, vessel formation, and transplanted cell survival more than untreated MSC transplantation does. Augmented functional recovery following MSC transplantation is blocked by PrP^C downregulation. Several studies in animals have shown that this compound, an endogenous ambiphilic bile acid, can inhibit unfolded protein response dysfunction and ameliorate ER stress. Its administration attenuates HDM-induced ER stress, airway inflammation, mucus metaplasia, airway remodeling, and methacholine-induced AHR.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28004805/ [2] https://pubmed.ncbi.nlm.nih.gov/27154200/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-Akt / Akt PrPc CHOP / Caspase-12 / Cleaved caspase-12 RIPK1 / RIPK3 / p-RIPK1 / p-RIPK3		28004805
Growth inhibition assay	Cell viability		30038553

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-04-21)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07328009	RECRUITING	Hepato Cellular Carcinoma (HCC)	Fudan University	2026-01-19	PHASE2
NCT06025630	RECRUITING	Hypertension	University of North Texas Health Science Center	2023-08-15	PHASE1; PHASE2
NCT07457632	NOT_YET_RECRUITING	Diabetic Macular Edema (DME)	University of Alabama at Birmingham	2026-10-01	PHASE2
NCT07100392	RECRUITING	Hepatocellular Carcinoma (HCC)	Fudan University	2025-08-14	PHASE2
NCT07064668	NOT_YET_RECRUITING	Hepatocellular Carcinoma	Tongji Hospital	2025-07-30	PHASE2
NCT07517276	NOT_YET_RECRUITING	Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development	Peking University First Hospital	2026-04-02	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Tauroursodeoxycholic Acid (TUDCA) ER Stress Inhibitor

Chemical Structure

Molecular Weight: 499.70